Results 31 to 40 of about 10,598 (216)

Analysis of NTRK mutation and clinicopathologic factors in lung cancer patients in northeast China

The International Journal of Biological Markers, 2020
Objective: NTRK mutations and clinicopathological factors in patients with lung cancer in northeast China were analyzed by next-generation sequencing (NGS), and references were provided for patients with NTRK mutations undergoing targeted therapy in ...
Hui Li, Shi Yan, Ying Liu, Lixia Ma, Xianhong Liu, Yan Liu, Ying Cheng   +6 more
doaj   +1 more source

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance

Frontiers in Oncology, 2022
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer (NSCLC) with a frequency of approximately less than 1%.
Fangfang Liu, Yuxuan Wei, Huan Zhang, Jizong Jiang, Peng Zhang, Qian Chu   +5 more
doaj   +1 more source

Comparison of patient characteristics for the unselected NTRK^–, matched NTRK⁻and NTRK⁺ cohorts.

, 2022
Comparison of patient characteristics for the unselected NTRK–, matched NTRK−and NTRK+ cohorts.
Solange Peters (318041), George D. Demetri (13215254), Laura Perez (3414401), Jessica Davies (3927101), Derrek P. Hibar (4502119), Olivier Humblet (2285017), Sophia L. Maund (11189433)   +6 more
core   +1 more source

gene amplification in patients with metastatic cancer [PDF]

Precision and Future Medicine, 2017
Purpose Neurotropic tropomyosin receptor kinase (NTRK) fusions have been identified in a variety of cancers, and tyrosine kinase inhibitors targeting the tropomyosin receptor kinase (TRK) receptor are currently in clinical trials. However, no reports are
Su Jin Lee, Nayoung K. D. Kim, Se-Hoon Lee, Seung Tae Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Woong Yang Park, Hee Jin Bang, Kyoung-Mee Kim, Keunchil Park, Jeeyun Lee   +13 more
doaj   +1 more source

Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With Subclonal NTRK1 Fusion: Case Report

JTO Clinical and Research Reports, 2023
The NTRK genes encode the TRK proteins. NTRK fusions lead to constitutively active, ligand-independent downstream signaling. NTRK fusions are implicated in up to 1% of all solid tumors and 0.2% of NSCLC.
Mary C. Boulanger, MD, Jennifer S. Temel, MD, Mari Mino-Kenudson, MD, Lauren L. Ritterhouse, MD, PhD, Ibiayi Dagogo-Jack, MD   +4 more
doaj   +1 more source

Identifying patients with NTRK fusion cancer [PDF]

Annals of Oncology, 2019
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer.
Solomon, J P, Benayed, R, Hechtman, J F, Ladanyi, M   +3 more
openaire   +3 more sources

Tester for deteksjon av NTRK genfusjoner hos pasienter med lokalavanserte eller metastatiske solide svulster. En metodevurdering. [PDF]

, 2022
Key messages The Norwegian Institute of Public Health has been commissioned to assess molecular tests for the identification of NTRK gene fusions in locally advanced or metastatic solid tumours.
Hamidi Ashtiani, Vida, Meneses Echavez, Jose Francisco, Bidonde Torre, Maria Julia, Flodgren, Gerd Monika   +3 more
core   +1 more source

Pediatric NTRK fusion sarcomas [PDF]

, 2020
Abstract Background While ETV6-NTRK3 fusion is common in infantile fibrosarcoma, NTRK1 fusion in pediatric sarcoma is extremely rare and consequently not well known. Herein, we evaluated NTRK1 fusion pediatric sarcomas to determine their clinicopathological nature and differential diagnosis from classic ETV6-NTRK3 fusion infantile fibrosarcoma.
Jeongwan Kang, Jin Woo Park, Jae-Kyung Won, Jeong Mo Bae, Hongseok Yun, Seung-Ki Kim, Jung Yoon Choi, Hyoung Jin Kang, Joo Heon Shin, Sung-Hye Park   +9 more
openaire   +1 more source

Comparison of selected biomarkers and genetic alteration status for the unselected NTRK^–, matched NTRK⁻and NTRK⁺ cohorts.

, 2022
Abbreviations: FH-FMI CGDB, Flatiron Health–Foundation Medicine clinicogenomic database; MSI, microsatellite instability; MSI-H, high MSI; MSI-I, intermediate MSI; MSS, microsatellite stability; NA, not available; NTRK-, neurotrophic tropomyosin receptor
Solange Peters (318041), George D. Demetri (13215254), Laura Perez (3414401), Jessica Davies (3927101), Derrek P. Hibar (4502119), Olivier Humblet (2285017), Sophia L. Maund (11189433)   +6 more
core   +1 more source

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

npj Precision Oncology, 2021
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers in solid tumours. This study aimed to interrogate a large real-world database of comprehensive genomic profiling data to describe the genomic landscape and prevalence
C. B. Westphalen, M. G. Krebs, C. Le Tourneau, E. S. Sokol, S. L. Maund, T. R. Wilson, D. X. Jin, J. Y. Newberg, D. Fabrizio, L. Veronese, M. Thomas, F. de Braud   +11 more
doaj   +1 more source